Does Cannabis Use Reduce Cirrhosis Risk in HCV Patients?

In an observation of a large pool of patients with hepatitis C virus (HCV), cannabis users had a lower prevalence of liver cirrhosis, more favorable health status at hospital discharge, and lower total health care costs than non-users. Adeyinka Adejumo, lead author of the study and graduate student at the University of Massachusetts Intercampus Program in Biomedical Engineering and Biotechnology, and colleagues indicated the findings add to a relationship

The Week in Review: April 20 – April 27, 2018

Friday, April 27, 2018 News Recap: Warnings: Synthetic cannabinoids and Hepatitis A could be a fatal combination. On April 9, 2018, the Missouri Department of Health and Senior Services (DHSS) issued a news release – “Use of Synthetic Cannabinoids Linked to Severe Bleeding in the US,” informing the public about the national outbreak of bleeding illnesses among those consuming synthetic cannabinoids which appear to have been contaminated with a long-...

NCCN: Screen for Liver Cancer in Patients at Risk

In the last 20 years in the United States, the incidence of hepatocellular carcinoma (HCC) has tripled from about 2 to 7 per 100,000 adults. In addition to the rising incidence, the cancer is also one of the most deadly, with a 5-year survival rate of only 18%. These comments were made here by Anne Covey, MD, a radiologist from the Memorial Sloan Kettering Cancer Center, New York City, at the National Comprehensive Cancer Network (NCCN) 23rd Annual Confer

The Week in Review: December 1 – December 8, 2017

Friday, December 8, 2017 News Recap: URGENT BC Patient and Caregiver Input Request: Vosevi. We need to hear your voice! Patient and Caregiver input is requested by BC PharmaCare on Gilead’s combo of sofosbuvir, velpatasvir, and voxilaprevir (SOF-VEL-VOX or Vosevi™) for Genotypes 1-6. Personal Stories This week we have two great stories of triumphing over HepC: Aidain’s ‘I will never forget the day I found out I had hepatitis c’, and Patric...

A South American amphibian could potentially hold the key in curing cirrhosis

The unique liver function of a South American amphibian, Siphonops annulatus, could pave the way to finding a cure to the devastating liver condition cirrhosis, a new study published in the prestigious Journal of Anatomy reports. Researchers from the University of Surrey (UK), the Federal University of São Paulo and the Butantan Institute in Brazil used an innovative 3D liver cell examination to explore the liver function of this snake-like amphibian. Dur

The Week in Review: October 13 – October 20, 2017

Friday, October 20, 2017 News Recap: Disease Management: Women: Hepatitis C in pregnancy: screening, treatment, and management. Hepatitis C (HCV) during pregnancy is associated with serious, adverse outcomes. Infants born to women with HCV are more likely to experience fetal growth restriction and low birth weight. For women, chronic HCV is associated with progressive liver damage and, during pregnancy, can be transmitted from the mother to the fe...

SVR reduces hepatic venous pressure gradient, portal hypertension persists

Sustained virologic response correlated with reduced hepatic venous pressure gradient in patients with HCV-associated cirrhosis, according to a recently published study. However, clinically significant portal hypertension continued to persist in most patients. “Development of [clinically significant portal hypertension] is a hallmark in the natural history of cirrhosis because it is associated with a higher risk of hepatic decompensation, and increased ri

Liver pressure has ‘come of age,’ aids management of liver disease

ORLANDO — Measuring hepatic pressure should be done by gastroenterologists and hepatologists because it can best direct treatment and outcomes, according to an international expert at the World Congress of Gastroenterology at ACG 2017. “Liver pressure has come of age. Gastroenterologists and hepatologists besides endoscopy should learn to measure pressures, should use it in routine practice like blood pressure measurements,” Shiv Kumar Sarin, MD, DM, dire

The Week in Review: September 15 – September 22, 2017

Friday, September 22, 2017 News Recap: Access to Treatment: This was a good week in terms of treatment access (but not, unfortunately, in terms of weather or seismic activity: How very, very sad).  Imagine being sick or on treatment in one of these stricken areas! In Canada Epclusa was approved for use in persons co-infected with HIV. This is very good news. Gilead Receives Approval in Canada for Expanded Indication of EPCLUSA® (Sofosbuvir/Velpat...

In HBV, high core-related antigen levels predict cirrhosis

Elevated hepatitis B virus core-related antigen levels significantly increased the risk for progression to cirrhosis among patients with chronic hepatitis B who are hepatitis B e antigen-negative and are not receiving nucleos(t)ide analogue therapy, according to recently published data. “Recently, various indices of liver fibrosis based on clinical and biological data have been reported to be useful predictors of fibrosis in liver disease,” Toshifumi Tada